{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:14:16Z","timestamp":1780496056985,"version":"3.54.1"},"reference-count":170,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR136009"],"award-info":[{"award-number":["NIHR136009"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Attention deficit hyperactivity disorder is characterised by inattention, impulsivity and hyperactivity. Diagnosis is complex and time-consuming. Medication requires careful selection and dose titration. Technologies for objective measures of attention deficit hyperactivity disorder that use motion sensors to measure hyperactivity (\u2018sensor continuous performance tests\u2019) may help improve the diagnostic process and medication management when used in addition to clinical assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether sensor continuous performance tests are clinically effective and cost-effective to the National Health Service. Specific objectives were to determine the effectiveness of sensor continuous performance tests for:<\/jats:p>\n                    <jats:list list-type=\"order\">\n                      <jats:list-item>\n                        <jats:p>diagnosis of attention deficit hyperactivity disorder in people referred with suspected attention deficit hyperactivity disorder<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>diagnosis of attention deficit hyperactivity disorder in people referred with suspected attention deficit hyperactivity disorder for whom current assessment cannot reach a diagnosis<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>during initial dose titration and treatment decisions for people with attention deficit hyperactivity disorder<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>evaluating treatment effectiveness during long-term treatment monitoring for people with attention deficit hyperactivity disorder.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and economic model (searches completed 17 November 2023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Objective 1 [29 studies \u2013 25 QbTest (QbTech Ltd., Stockholm, Sweden), 2 EF Sim (Peili Vision, Oulu, Finland) and 2 Nesplora Kids (Giunti Psychometrics, Florence, Italy)]: most evidence was in children. The AQUA trial was the only study to evaluate the QbTest in combination with clinical assessment and included a comparison with clinical assessment alone. Accuracy was similar and there was no statistical evidence of a difference between groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2005=\u20050.14), but the study was at high risk of bias. The AQUA trial reported that adding QbTest to the diagnostic process resulted in fewer appointments to reach a diagnosis, reduced consultation time, greater clinician confidence and exclusion of the diagnosis in a more children. Findings were supported by limited data from uncontrolled before\u2013after studies. Qualitative and survey data reported increased clinician confidence in clinical decision-making, reduced time to diagnostic decision and improved communication. Barriers to implementation included staffing, training, technology requirements and length and repetitive content of the test. We found that using QbTest in addition to clinical assessment was likely cost-effective due to the reduced time waiting for assessment, reduced appointments until diagnosis and a higher proportion receiving treatment benefits.\n                    <\/jats:p>\n                    <jats:p>Objective 3 (six studies): All evaluated QbTest and most had concerns with risk of bias. Qualitative and survey data suggested that healthcare staff and families valued the QbTest for dose titration, checking medication utility and improving medication adherence. Some data suggested that results may not increase patient understanding and some clinicians highlighted logistical challenges.<\/jats:p>\n                    <jats:p>No studies were identified for objectives 2 and 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that QbTesting as part of the diagnostic workup for attention deficit hyperactivity disorder in children (age\u00a0&lt;\u200518 years), when used in combination with clinical assessment, may be cost-effective. This finding was robust to nearly all assumptions made in the model. There are insufficient data on other sensor continuous performance tests in adults or on medication management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Future work<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Diagnostic accuracy study evaluating comparing each of the sensor continuous performance tests plus clinical assessment. This should consider accuracy across different patient subgroups.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Trial comparing patient outcomes and process measures in adults and children tested with and without sensor continuous performance tests with separate analyses for difficult-to-diagnose patients.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Trial evaluating the role of sensor continuous performance tests in medication management, including long-term follow-up.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>Lack of good-quality data on all tests, both for diagnosis and medication management, particularly when evaluated in combination with clinical information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-8\">\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>This study is registered as PROSPERO CRD42023482963.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-9\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>\n                      This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136009) and is published in full in\n                      <jats:italic>Health Technology Assessment<\/jats:italic>\n                      ; Vol. 29, No. 58. See the NIHR Funding and Awards website for further award information.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/drdr7171","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T10:26:36Z","timestamp":1738837596000},"page":"1-216","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0969-602X","authenticated-orcid":true,"given":"Eve","family":"Tomlinson","sequence":"first","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2321-2546","authenticated-orcid":true,"given":"Mary","family":"Ward","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-5738","authenticated-orcid":true,"given":"Josephine","family":"Walker","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-2742","authenticated-orcid":true,"given":"Melissa","family":"Benevente","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-0667","authenticated-orcid":true,"given":"Hanyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-5607","authenticated-orcid":true,"given":"Chris","family":"Cooper","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4265-2854","authenticated-orcid":true,"given":"Hayley E","family":"Jones","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-2371","authenticated-orcid":true,"given":"Amanda","family":"Owen-Smith","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8883-0167","authenticated-orcid":true,"given":"Catalina","family":"Lopez Manzano","sequence":"additional","affiliation":[{"name":"Patient representative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"James","sequence":"additional","affiliation":[{"name":"Patient representative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-8078","authenticated-orcid":true,"given":"Dietmar","family":"Hank","sequence":"additional","affiliation":[{"name":"Avon and Wiltshire Mental Health Partnership NHS Trust, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-4313","authenticated-orcid":true,"given":"Richard","family":"Lee-Kelland","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-3205","authenticated-orcid":true,"given":"Nicky J","family":"Welton","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5682","authenticated-orcid":true,"given":"Penny","family":"Whiting","sequence":"additional","affiliation":[{"name":"Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,11]]},"reference":[{"key":"key2026042012384700_ref1-bib1","volume-title":"[FINAL PROTOCOL] Technologies for the Assessment of Attention Deficit Hyperactivity Disorder","author":"Bristol TAG","year":"2023"},{"key":"key2026042012384700_ref2-bib2","volume-title":"Symptoms \u2013 Attention Deficit Hyperactivity Disorder (ADHD)","author":"NHS","year":"2021"},{"key":"key2026042012384700_ref3-bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2215-0366(17)30487-X","article-title":"ADHD in children and young people: prevalence, care pathways, and service provision","volume":"5","author":"Sayal","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"key2026042012384700_ref4-bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12888-021-03235-w","article-title":"Temporal trends in annual incidence rates for psychiatric disorders and self-harm among children and adolescents in the UK, 2003\u20132018","volume":"21","author":"Cybulski","year":"2021","journal-title":"BMC Psychiatry"},{"key":"key2026042012384700_ref5-bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/7854_2022_329","article-title":"ADHD in children and adults: diagnosis and prognosis","volume":"57","author":"Leffa","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"key2026042012384700_ref6-bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fpsyt.2018.00331","article-title":"Prevalence of attention deficit hyperactivity disorder in detention settings: a systematic review and meta-analysis","volume":"9","author":"Baggio","year":"2018","journal-title":"Front Psychiatry"},{"key":"key2026042012384700_ref7-bib7","volume-title":"Prevalence of ADHD in Adult Prisoners: A Re-analysis","author":"Fazel","year":"2023"},{"key":"key2026042012384700_ref8-bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00787-016-0841-6","article-title":"The impact of ADHD on the health and well-being of ADHD children and their siblings","volume":"25","author":"Peasgood","year":"2016","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref9-bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pop.2007.04.012","article-title":"ADHD in children, adolescents, and adults","volume":"34","author":"Katragadda","year":"2007","journal-title":"Primary Care"},{"key":"key2026042012384700_ref10-bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1521\/adhd.10.3.9.20553","article-title":"The impact of ADHD on marriage","volume":"10","author":"Robin","year":"2002","journal-title":"ADHD Report"},{"key":"key2026042012384700_ref11-bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.euroneuro.2018.08.001","article-title":"Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan","volume":"28","author":"Franke","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"key2026042012384700_ref12-bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/ipm.2017.21","article-title":"The impact of attention deficit hyperactivity disorder (ADHD) in adulthood: a qualitative study","volume":"35","author":"Watters","year":"2018","journal-title":"Ir J Psychol Med"},{"key":"key2026042012384700_ref13-bib13","volume-title":"Attention Deficit Hyperactivity Disorder (ADHD)","author":"NHS","year":"2021"},{"key":"key2026042012384700_ref14-bib14","volume-title":"Attention Deficit Hyperactivity Disorder in Children","author":"BMJ Best Practice","year":"2023"},{"key":"key2026042012384700_ref15-bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.157.5.816","article-title":"Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type","volume":"157","author":"Biederman","year":"2000","journal-title":"Am J Psychiatry"},{"key":"key2026042012384700_ref16-bib16","volume-title":"NG87: Attention Deficit Hyperactivity Disorder: Diagnosis and Management","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key2026042012384700_ref17-bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pnp.198","article-title":"Role of computerised continuous performance task tests in ADHD","volume":"15","author":"Ogundele","year":"2011","journal-title":"Prog Neurol Psychiatry"},{"key":"key2026042012384700_ref18-bib18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jcpp.12921","article-title":"The impact of a computerised test of attention and activity (QbTest) on diagnostic decision-making in children and young people with suspected attention deficit hyperactivity disorder: single-blind randomised controlled trial","volume":"59","author":"Hollis","year":"2018","journal-title":"J Child Psychol Psychiatry"},{"key":"key2026042012384700_ref19-bib19","volume-title":"ADHD in Adults: Good Practice Guidelines","author":"Royal College of Psychiatrists in Scotland","year":"2017"},{"key":"key2026042012384700_ref20-bib20","volume-title":"Petitions Committee: ADHD and ASD (Autism) Assessment Waiting Times","author":"House of Commons"},{"key":"key2026042012384700_ref21-bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjb.2023.88","article-title":"UK adult ADHD services in crisis","volume":"48","author":"Smith","year":"2024","journal-title":"BJPsych Bulletin"},{"key":"key2026042012384700_ref22-bib22","volume-title":"Faster and More Cost-effective ADHD Diagnosis for Children","author":"Health Innovation East Midlands"},{"key":"key2026042012384700_ref24-bib24","volume-title":"International Classification of Diseases (ICD-11) 11th Revision","author":"World Health Organization"},{"key":"key2026042012384700_ref25-bib25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jaac.2021.11.031","article-title":"Systematic review and meta-analysis: screening tools for attention-deficit\/hyperactivity disorder in children and adolescents","volume":"61","author":"Mulraney","year":"2022","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref26-bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00787-015-0798-x","article-title":"The clinical utility of the continuous performance test and objective measures of activity for diagnosing and monitoring ADHD in children: a systematic review","volume":"25","author":"Hall","year":"2016","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref27-bib27","volume-title":"Treatment \u2013 Attention Deficit Hyperactivity Disorder (ADHD)","author":"NHS","year":"2021"},{"key":"key2026042012384700_ref28-bib28","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.pharmthera.2021.107940","article-title":"Evidence-based pharmacological treatment options for ADHD in children and adolescents","volume":"230","author":"Mechler","year":"2022","journal-title":"Pharmacol Ther"},{"key":"key2026042012384700_ref29-bib29","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/1087054720903361","article-title":"Is the QbMini a valid instrument for ADHD assessment? [References]. DP \u2013 Aug 2021","volume":"25","author":"Hamadache","year":"2021","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref30-bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/jcpp.13901","article-title":"Practitioner review: clinical utility of the QbTest for the assessment and diagnosis of attention-deficit\/hyperactivity disorder \u2013 a systematic review and meta-analysis","volume":"65","author":"Bellato","year":"2023","journal-title":"J Child Psychol Psychiatry"},{"key":"key2026042012384700_ref31-bib31","volume-title":"Focus ADHD National Programme Evaluation","author":"McKenzie","year":"2022"},{"key":"key2026042012384700_ref32-bib32","volume-title":"[MIB318] QbTest for the Assessment of Attention Deficit Hyperactivity Disorder (ADHD)","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2026042012384700_ref34-bib34","volume-title":"NICE Health Technology Evaluations: The Manual (PMG36)","author":"National Institute for Health Care Excellence","year":"2022"},{"key":"key2026042012384700_ref35-bib35","volume-title":"Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy","author":"Deeks","year":"2022"},{"key":"key2026042012384700_ref36-bib36","doi-asserted-by":"crossref","first-page":"m2632","DOI":"10.1136\/bmj.m2632","article-title":"Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist","volume":"370","author":"Salameh","year":"2020","journal-title":"BMJ"},{"key":"key2026042012384700_ref37-bib37","doi-asserted-by":"crossref","first-page":"e1001333","DOI":"10.1371\/journal.pmed.1001333","article-title":"PRISMA-equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity","volume":"9","author":"Welch","year":"2012","journal-title":"PLOS Med"},{"key":"key2026042012384700_ref38-bib38","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key2026042012384700_ref39-bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: a new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"key2026042012384700_ref40-bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O\u2019Neill","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"key2026042012384700_ref41-bib41","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/10870547231174035","article-title":"The structure and diagnostic accuracy of the QbTest in pediatric ADHD: a retrospective clinical study","volume":"27","author":"Stevanovic","year":"2023","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref42-bib42","volume-title":"Statistical Testing for AUC Data [R Package auctestr Version 1.0.0]. R-Project.org","author":"Gardner","year":"2017"},{"key":"key2026042012384700_ref43-bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"key2026042012384700_ref44-bib44","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2026042012384700_ref45-bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key2026042012384700_ref46-bib46","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"key2026042012384700_ref47-bib47","volume-title":"CASP Checklists \u2013 Critical Appraisal Checklists","author":"Critical Appraisal Skills Programme (CASP)","year":"2024"},{"key":"key2026042012384700_ref48-bib48","doi-asserted-by":"crossref","first-page":"100031","DOI":"10.1016\/j.metip.2020.100031","article-title":"A checklist to assess the quality of survey studies in psychology","volume":"3","author":"Protogerou","year":"2020","journal-title":"Methods Psychol"},{"key":"key2026042012384700_ref49-bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13690-022-00953-9","article-title":"Metadta: a Stata command for meta-analysis and meta-regression of diagnostic test accuracy data \u2013 a tutorial","volume":"80","author":"Nyaga","year":"2022","journal-title":"Arch Pub Health"},{"key":"key2026042012384700_ref50-bib50","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"key2026042012384700_ref51-bib51","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jclinepi.2006.06.011","article-title":"Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach","volume":"59","author":"Chu","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"key2026042012384700_ref52-bib52","volume-title":"metagen: Generic Inverse Variance Meta-analysis","author":"RDocumentation [DataCamp]","year":"n.r"},{"key":"key2026042012384700_ref53-bib53","volume-title":"Breakthroughs in Statistics: Methodology and Distribution","author":"Fisher","year":"1992"},{"key":"key2026042012384700_ref54-bib54","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/j.1365-2648.2011.05636.x","article-title":"Pragmatism as the philosophical foundation for the Joanna Briggs meta-aggregative approach to qualitative evidence synthesis","volume":"67","author":"Hannes","year":"2011","journal-title":"J Adv Nurs"},{"key":"key2026042012384700_ref55-bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/13854046.2019.1696409","article-title":"Diagnosing attention-deficit\/hyperactivity disorder (ADHD) in young adults: a qualitative review of the utility of assessment measures and recommendations for improving the diagnostic process","volume":"35","author":"Marshall","year":"2021","journal-title":"Clin Neuropsychol"},{"key":"key2026042012384700_ref56-bib56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00787-020-01557-w","article-title":"Video games for the assessment and treatment of attention-deficit\/hyperactivity disorder: a systematic review","volume":"31","author":"Pe\u00f1uelas-Calvo","year":"2022","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref57-bib57","doi-asserted-by":"crossref","first-page":"101870","DOI":"10.1016\/j.cpr.2020.101870","article-title":"A systematic review evaluating the implementation of technologies to assess, monitor and treat neurodevelopmental disorders: a map of the current evidence","volume":"80","author":"Valentine","year":"2020","journal-title":"Clin Psychol Rev"},{"key":"key2026042012384700_ref58-bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.37511\/tesis.v17n1a10","article-title":"Programas de intervenci\u00f3n basados en tecnolog\u00edas para ni\u00f1os y adolescentes diagnosticados con TDAH: Una revisi\u00f3n sistem\u00e1tica","volume":"17","author":"Cabas-Hoyos","year":"2022","journal-title":"Tesis Psicol\u00f3gica"},{"key":"key2026042012384700_ref59-bib59","doi-asserted-by":"crossref","first-page":"e17450179276630","DOI":"10.2174\/0117450179276630231030093814","article-title":"QbTest for monitoring medication treatment response in ADHD: a systematic review","volume":"19","author":"Gustafsson","year":"2023","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"key2026042012384700_ref60-bib60","doi-asserted-by":"crossref","first-page":"102213","DOI":"10.1016\/j.cpr.2022.102213","article-title":"Virtual reality in the diagnostic and therapy for mental disorders: a systematic review","volume":"98","author":"Wiebe","year":"2022","journal-title":"Clin Psychol Rev"},{"key":"key2026042012384700_ref61-bib61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/mhs2.43","article-title":"QbTest in the clinical assessment of attention deficit hyperactivity disorder: a review of the evidence","volume":"1","author":"Gustafsson","year":"2023","journal-title":"Mental Health Sci"},{"key":"key2026042012384700_ref62-bib62","article-title":"Evaluation of the role of Qb testing in attention deficit hyperactivity disorder","volume":"94","author":"Sharma","year":"2009","journal-title":"Arch Dis Child"},{"key":"key2026042012384700_ref63-bib63","article-title":"Estudio de sensibilidad de un nuevo m\u00e9todo diagn\u00f3stico para el TDAH: Aula Nesplora","volume":"54","author":"Rufo-Campos","year":"2012","journal-title":"Rev Neurol (Paris)"},{"key":"key2026042012384700_ref64-bib64","first-page":"A70","article-title":"Implementing QB testing for ADHD: evaluating value in a DGH setting","volume":"107","author":"Sharma","year":"2022","journal-title":"Arch Dis Child"},{"key":"key2026042012384700_ref65-bib65","first-page":"656","article-title":"Additiver Nutzen des QbTests in der Diagnostik der Aufmerksamkeitsdefizit-\/Hyperaktiv- ita\u0308tssto\u0308rung im Kindesalter (Manuscript in preparation)","volume":"30","author":"Soff","year":"2017"},{"key":"key2026042012384700_ref66-bib66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/sjop.12499","article-title":"Incremental clinical utility of continuous performance tests in childhood ADHD \u2013 an evidence-based assessment approach","volume":"60","author":"Tallberg","year":"2019","journal-title":"Scand J Psychol"},{"key":"key2026042012384700_ref67-bib67","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1087054715595697","article-title":"ADHD and the QbTest: diagnostic validity of QbTest","volume":"22","author":"Hult","year":"2018","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref68-bib68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fpsyt.2020.00216","article-title":"The quantified behavioral test-a confirmatory test in the diagnostic process of adult ADHD?","volume":"11","author":"Brunkhorst-Kanaan","year":"2020","journal-title":"Front Psychiatry"},{"key":"key2026042012384700_ref69-bib69","volume-title":"Transforming ADHD Care across the East Midlands: An Evaluation Report. East Midlands Academic Health Network","author":"Humphreys","year":"2018"},{"key":"key2026042012384700_ref70-bib70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1087054718787034","article-title":"The quantified behavioral test failed to differentiate ADHD in adolescents with neurodevelopmental problems","volume":"25","author":"Johansson","year":"2021","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref71-bib71","volume-title":"Assessment of ARVO Web-based Software for Evaluating Attention-Deficit\/Hyperactive Disorder (ADHD) Symptoms in Children","author":"NCT05846815","year":"2023"},{"key":"key2026042012384700_ref72-bib72","doi-asserted-by":"crossref","first-page":"e064951","DOI":"10.1136\/bmjopen-2022-064951","article-title":"Using an objective computer task (QbTest) to aid the identification of attention deficit hyperactivity disorder (ADHD) in the Children and Young People Secure Estate (CYPSE): a feasibility randomised controlled trial","volume":"12","author":"Chitsabesan","year":"2022","journal-title":"BMJ Open"},{"key":"key2026042012384700_ref73-bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5093\/psed2018a18","article-title":"Virtual reality-based assessment and rating scales in ADHD diagnosis","volume":"25","author":"Zulueta","year":"2019","journal-title":"Psicologia Educativa"},{"key":"key2026042012384700_ref74-bib74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/08039488.2012.762940","article-title":"Quantitative and subjective behavioural aspects in the assessment of attention-deficit hyperactivity disorder (ADHD) in adults","volume":"68","author":"S\u00f6derstr\u00f6m","year":"2014","journal-title":"Nord J Psychiatry"},{"key":"key2026042012384700_ref75-bib75","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1177\/10870547211044214","article-title":"Quantifying ADHD symptoms in open-ended everyday life contexts with a new virtual reality task","volume":"26","author":"Seesj\u00e4rvi","year":"2022","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref76-bib76","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1745017901208010134","article-title":"Objective measures of behavior manifestations in adult ADHD and differentiation from participants with bipolar II disorder, borderline personality disorder, participants with disconfirmed ADHD as well as normative participants","volume":"8","author":"Edebol","year":"2012","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"key2026042012384700_ref77-bib77","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1002\/mpr.1822","article-title":"Objective measurement of attention deficit hyperactivity disorder symptoms outside the clinic using the QbCheck: reliability and validity","volume":"29","author":"Ulberstad","year":"2020","journal-title":"Int J Methods Psychiatr Res"},{"key":"key2026042012384700_ref78-bib78","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/gps.5163","article-title":"Objective assessment of attention-deficit\/hyperactivity disorder in older adults compared with controls using the QbTest","volume":"34","author":"Bijlenga","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"key2026042012384700_ref79-bib79","first-page":"48","article-title":"Measuring adult attention deficit hyperactivity disorder using the quantified behavior test plus","volume":"2","author":"Edebol","year":"2013","journal-title":"Psychology J"},{"key":"key2026042012384700_ref80-bib80","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.psychres.2016.06.042","article-title":"The incremental validity of a computerised assessment added to clinical rating scales to differentiate adult ADHD from autism spectrum disorder","volume":"243","author":"Groom","year":"2016","journal-title":"Psychiatry Res"},{"key":"key2026042012384700_ref81-bib81","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/10870547221079798","article-title":"Efficacy of continuous performance testing in adult ADHD in a clinical sample using QbTest","volume":"26","author":"Adamou","year":"2022","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref82-bib82","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1087054715618788","article-title":"Diagnosing ADHD in adults: an examination of the discriminative validity of neuropsychological tests and diagnostic assessment instruments","volume":"22","author":"Pettersson","year":"2018","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref83-bib83","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12993-018-0143-x","article-title":"Assessing ADHD symptoms in children and adults: evaluating the role of objective measures","volume":"14","author":"Emser","year":"2018","journal-title":"Behav Brain Funct"},{"key":"key2026042012384700_ref84-bib84","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5964\/ejop.v7i3.143","article-title":"In search for objective measures of hyperactivity, impulsivity and inattention in adult attention deficit hyperactivity disorder using the quantified behavior test plus","volume":"7","author":"Edebol","year":"2011","journal-title":"Eur J Psychol"},{"key":"key2026042012384700_ref85-bib85","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/camh.12140","article-title":"Innovations in practice: an objective measure of attention, impulsivity and activity reduces time to confirm attention deficit\/hyperactivity disorder diagnosis in children \u2013 a completed audit cycle","volume":"21","author":"Hall","year":"2016","journal-title":"Child Adolesc Ment Health"},{"key":"key2026042012384700_ref86-bib86","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1192\/pb.bp.110.032144","article-title":"Assessments for attention-deficit hyperactivity disorder: use of objective measurements","volume":"35","author":"Vogt","year":"2011","journal-title":"Psychiatrist"},{"key":"key2026042012384700_ref87-bib87","doi-asserted-by":"crossref","first-page":"105032","DOI":"10.1016\/j.childyouth.2020.105032","article-title":"The QbTest for ADHD assessment: impact and implementation in child and adolescent mental health services","volume":"114","author":"Pellegrini","year":"2020","journal-title":"Child Youth Serv Rev"},{"key":"key2026042012384700_ref88-bib88","unstructured":"Peli Vision Oy. Research Behind EFSim and Feedback from Pilot Tests [Unpublished Report]; (n.r.)."},{"key":"key2026042012384700_ref89-bib89","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1469-7610.2000.tb02345.x","article-title":"The development and well-being assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology","volume":"41","author":"Goodman","year":"2000","journal-title":"J Child Psychol Psychiatry"},{"key":"key2026042012384700_ref90-bib90","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jama.1994.03520100096046","article-title":"DSM-IV: diagnostic and statistical manual of mental disorders","volume":"272","author":"Bell","year":"1994","journal-title":"J Am Med Assoc"},{"key":"key2026042012384700_ref91-bib91","volume-title":"Highlights of Changes from DSM-IV-TR to DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"key2026042012384700_ref94-bib94","doi-asserted-by":"crossref","first-page":"f6172","DOI":"10.1136\/bmj.f6172","article-title":"Attention-deficit\/hyperactivity disorder: are we helping or harming?","volume":"347","author":"Thomas","year":"2013","journal-title":"BMJ"},{"key":"key2026042012384700_ref95-bib95","volume-title":"Kiddie-Sads-Present and Lifetime Version (K-SADS-PL)","author":"Kaufman","year":"1996"},{"key":"key2026042012384700_ref96-bib96","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1651-2227.2008.01025.x","article-title":"Validity and clinical feasibility of the ADHD rating scale (ADHD-RS): a Danish nationwide multicenter study","volume":"98","author":"Szomlaiski","year":"2009","journal-title":"Acta Paediatr"},{"key":"key2026042012384700_ref97-bib97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0033291704002892","article-title":"The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population","volume":"35","author":"Kessler","year":"2005","journal-title":"Psychol Med"},{"key":"key2026042012384700_ref98-bib98","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eurpsy.2010.12.010","article-title":"German validation of the Conners Adult ADHD Rating Scales (CAARS) II: reliability, validity, diagnostic sensitivity and specificity","volume":"27","author":"Christiansen","year":"2012","journal-title":"Eur Psychiatric Assoc"},{"key":"key2026042012384700_ref99-bib99","volume-title":"[TAP] Testbatterie zur Aufmerksamkeitspr\u00fcfung.Herzogenrath","author":"Zimmermann","year":"2012"},{"key":"key2026042012384700_ref100-bib100","volume-title":"KiTAP: Testbatterie zur Aufmerksamkeitspr\u00fcfungf\u00fcr Kinder KiTAP","author":"Zimmermann","year":"2003"},{"key":"key2026042012384700_ref101-bib101","volume-title":"Conners Adult Rating Scale and Autism Quotient-10","author":"Conners","year":"1999"},{"key":"key2026042012384700_ref102-bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1005653411471","article-title":"The Autism-Spectrum Quotient (AQ): evidence from Asperger syndrome\/high-functioning autism, males and females, scientists and mathematicians","volume":"31","author":"Baron-Cohen","year":"2001","journal-title":"J Autism Dev Disord"},{"key":"key2026042012384700_ref103-bib103","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/h0043220","article-title":"A continuous performance test of brain damage","volume":"20","author":"Rosvold","year":"1956","journal-title":"J Consult Psychol"},{"key":"key2026042012384700_ref104-bib104","volume-title":"Conners\u2019 Continuous Performance Test (CPT-II) Computer Programs for Windows Technical Guide and Software Manual","author":"Conners","year":"2000"},{"key":"key2026042012384700_ref105-bib105","volume-title":"Focus ADHD National Programme Evaluation","author":"McKenzie","year":"2022"},{"key":"key2026042012384700_ref106-bib106","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.mhpa.2013.09.002","article-title":"Associations between executive attention and objectively measured physical activity in adolescence: findings from ALSPAC, a UK cohort","volume":"6","author":"Booth","year":"2013","journal-title":"Ment Health Phys Act"},{"key":"key2026042012384700_ref107-bib107","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12888-017-1222-5","article-title":"Study of user experience of an objective test (QbTest) to aid ADHD assessment and medication management: a multi-methods approach","volume":"17","author":"Hall","year":"2017","journal-title":"BMC Psychiatry"},{"key":"key2026042012384700_ref108-bib108","doi-asserted-by":"crossref","first-page":"e035519","DOI":"10.1136\/bmjopen-2019-035519","article-title":"FACT: a randomised controlled trial to assess the feasibility of QbTest in the assessment process of attention deficit hyperactivity disorder (ADHD) for young people in prison \u2013 a feasibility trial protocol","volume":"10","author":"Lennox","year":"2020","journal-title":"BMJ Open"},{"key":"key2026042012384700_ref109-bib109","volume-title":"Feasibility Trial to Assess Attention Deficit Hyperactivity Disorder (ADHD) in the Criminal Justice System by Using QbTest (A Computer Task)","author":"ISRCTN17402196","year":"2019"},{"key":"key2026042012384700_ref110-bib110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40814-021-00788-1","article-title":"Optimising medication management in children and young people with ADHD using a computerised test (QbTest): a feasibility randomised controlled trial","volume":"7","author":"Williams","year":"2021","journal-title":"Pilot Feasibility Stud"},{"key":"key2026042012384700_ref111-bib111","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1073191107313888","article-title":"Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample","volume":"15","author":"Bussing","year":"2008","journal-title":"Assessment"},{"key":"key2026042012384700_ref112-bib112","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"key2026042012384700_ref113-bib113","volume-title":"QbTest for ADHD Cost-Benefit Analysis","author":"Kent Surrey Sussex Academic Health Science Network","year":"n.r"},{"key":"key2026042012384700_ref114-bib114","volume-title":"CG72: Attention Deficit Hyperactivity Disorder (update) Appendix 1: Cost-effectiveness Analysis: What Is the Cost Effectiveness of Parent Training Compared to No Treatment for Children with ADHD?","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2026042012384700_ref115-bib115","volume-title":"CG72: Attention Deficit Hyperactivity Disorder (Update) Appendix 2: Cost-effectiveness Analysis: Combination Treatment in Children and Adolescents","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2026042012384700_ref116-bib116","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1524-4733.2007.00256.x","article-title":"A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit\/hyperactivity disorder in the United Kingdom","volume":"11","author":"Cottrell","year":"2008","journal-title":"Value Health"},{"key":"key2026042012384700_ref117-bib117","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF03261873","article-title":"Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder: application of a matching-adjusted indirect comparison","volume":"10","author":"Erder","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"key":"key2026042012384700_ref118-bib118","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200822020-00006","article-title":"Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in the Netherlands","volume":"22","author":"Faber","year":"2008","journal-title":"CNS Drugs"},{"key":"key2026042012384700_ref119-bib119","doi-asserted-by":"crossref","first-page":"2381468319867629","DOI":"10.1177\/2381468319867629","article-title":"Cost-effectiveness of treatments in children with attention-deficit\/hyperactivity disorder: a continuous-time markov modeling approach","volume":"4","author":"Freriks","year":"2019","journal-title":"MDM Policy Pract"},{"key":"key2026042012384700_ref120-bib120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-244X-9-15","article-title":"A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit\/hyperactivity disorder in Spain","volume":"9","author":"Hong","year":"2009","journal-title":"BMC Psychiatry"},{"key":"key2026042012384700_ref121-bib121","doi-asserted-by":"crossref","first-page":"iii\u2013iv","DOI":"10.3310\/hta10230","article-title":"A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents","volume":"10","author":"King","year":"2006","journal-title":"Health Technol Assess"},{"key":"key2026042012384700_ref122-bib122","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10742-011-0076-4","article-title":"Characterizing patterns of care using administrative claims data: ADHD treatment in children","volume":"11","author":"Klein","year":"2011","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"key2026042012384700_ref123-bib123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12888-016-0708-x","article-title":"Is adjunctive pharmacotherapy in attention-deficit\/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD","volume":"16","author":"Lachaine","year":"2016","journal-title":"BMC Psychiatry"},{"key":"key2026042012384700_ref124-bib124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/1516-4446-2014-1516","article-title":"Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil","volume":"38","author":"Maia","year":"2016","journal-title":"Rev Bras Psiquiatr"},{"key":"key2026042012384700_ref125-bib125","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0149-2918(00)89086-4","article-title":"Pharmacotherapies for attention-deficit\/hyperactivity disorder: expected-cost analysis","volume":"23","author":"Marchetti","year":"2001","journal-title":"Clin Ther"},{"key":"key2026042012384700_ref126-bib126","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737167.2017.1271325","article-title":"A conceptual framework for a long-term economic model for the treatment of attention-deficit\/hyperactivity disorder","volume":"17","author":"Nagy","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key2026042012384700_ref127-bib127","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1586\/14737167.4.6.625","article-title":"Cost effectiveness of methylphenidate versus AMP\/DEX mixed salts for the first-line treatment of ADHD","volume":"4","author":"Narayan","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key2026042012384700_ref128-bib128","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1742-1241.2009.02090.x","article-title":"Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK","volume":"63","author":"Prasad","year":"2009","journal-title":"Int J Clin Pract"},{"key":"key2026042012384700_ref129-bib129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40273-015-0259-x","article-title":"Probabilistic Markov model estimating cost effectiveness of methylphenidate osmotic-release oral system versus immediate-release methylphenidate in children and adolescents: which information is needed?","volume":"33","author":"Schawo","year":"2015","journal-title":"PharmacoEconomics"},{"key":"key2026042012384700_ref130-bib130","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11632920-000000000-00000","article-title":"Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents","volume":"30","author":"Sikirica","year":"2012","journal-title":"PharmacoEconomics"},{"key":"key2026042012384700_ref131-bib131","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12402-016-0198-1","article-title":"A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy","volume":"8","author":"Sohn","year":"2016","journal-title":"Atten Defic Hyperact Disord"},{"key":"key2026042012384700_ref132-bib132","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13034-023-00664-1","article-title":"Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit\/hyperactivity disorder in Iran","volume":"17","author":"Tajik","year":"2023","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"key2026042012384700_ref133-bib133","first-page":"104","article-title":"Atomoxetine for the treatment of adults with attention deficit hyperactivity disorder: a cost-utility analysis in Spain","volume":"1","author":"Tockhorn-Heidenreich","year":"2015","journal-title":"Pharmacoeconomics Open Access"},{"key":"key2026042012384700_ref134-bib134","doi-asserted-by":"crossref","first-page":"e0127237","DOI":"10.1371\/journal.pone.0127237","article-title":"Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit\/hyperactivity disorder sub-optimally treated with immediate release methylphenidate","volume":"10","author":"van der Schans","year":"2015","journal-title":"PLOS ONE"},{"key":"key2026042012384700_ref135-bib135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3111\/200306079094","article-title":"A cost analysis of the management of attention-deficit\/hyperactivity disorder (ADHD) in children in the UK","volume":"6","author":"Vanoverbeke","year":"2003","journal-title":"J Med Econ"},{"key":"key2026042012384700_ref136-bib136","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40263-016-0354-3","article-title":"A cost-utility analysis of lisdexamfetamine versus atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder and inadequate response to methylphenidate","volume":"30","author":"Zimovetz","year":"2016","journal-title":"CNS Drugs"},{"key":"key2026042012384700_ref137-bib137","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10198-016-0864-4","article-title":"A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit\/hyperactivity disorder in the UK","volume":"19","author":"Zimovetz","year":"2018","journal-title":"Eur J Health Econ"},{"key":"key2026042012384700_ref138-bib138","volume-title":"A Review of Therapies for Attentiondeficit\/Hyperactivity Disorder","author":"Miller","year":"1998"},{"key":"key2026042012384700_ref139-bib139","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","article-title":"TECH-VER: a verification checklist to reduce errors in models and improve their credibility","volume":"37","author":"B\u00fcy\u00fckkaramikli","year":"2019","journal-title":"PharmacoEconomics"},{"key":"key2026042012384700_ref140-bib140","volume-title":"Unit Costs of Health and Social Care programme (2022 \u2013 2027)","author":"Personal Social Services Research Unit (PSSRU)","year":"n.r"},{"key":"key2026042012384700_ref141-bib141","volume-title":"National Cost Collection for the NHS","author":"NHS","year":"n.r"},{"key":"key2026042012384700_ref142-bib142","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40263-013-0104-8","article-title":"Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit\/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study","volume":"27","author":"Dittmann","year":"2013","journal-title":"CNS Drugs"},{"key":"key2026042012384700_ref143-bib143","first-page":"119","article-title":"Association between quality of life and treatment response in children with attention deficit hyperactivity disorder and their parents","volume":"17","author":"van der Kolk","year":"2014","journal-title":"J Ment Health Policy Econ"},{"key":"key2026042012384700_ref144-bib144","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0272989X04273140","article-title":"Health state utilities for childhood attention-deficit\/hyperactivity disorder based on parent preferences in the United Kingdom","volume":"25","author":"Secnik","year":"2005","journal-title":"Med Decis Making"},{"key":"key2026042012384700_ref145-bib145","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1177\/1087054720925899","article-title":"What is the health and well-being burden for parents living with a child with ADHD in the United Kingdom?","volume":"25","author":"Peasgood","year":"2021","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref146-bib146","volume-title":"2023-25 NHS Payment Scheme (Amended)","author":"NHS England","year":"2024"},{"key":"key2026042012384700_ref147-bib147","volume-title":"CPI Index 06.2.1\/3: Medical Services and Paramedical Services: 2015=100","author":"Office for National Statistics (ONS)","year":"n.r"},{"key":"key2026042012384700_ref148-bib148","volume-title":"British National Formulary (BNF)","author":"National Institute for Health and Care Excellence","year":"2024"},{"key":"key2026042012384700_ref149-bib149","volume-title":"Considerations When Prescribing Modified-Release Methylphenidate","author":"Specialist Pharmacy Service","year":"2023"},{"key":"key2026042012384700_ref150-bib150","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.euroneuro.2014.09.014","article-title":"Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, controlled, phase III trial","volume":"24","author":"Hervas","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"key2026042012384700_ref151-bib151","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00787-009-0042-7","article-title":"Atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia","volume":"19","author":"Martenyi","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref152-bib152","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","article-title":"Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response","volume":"165","author":"Newcorn","year":"2008","journal-title":"Am J Psychiatry"},{"key":"key2026042012384700_ref153-bib153","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/cap.2008.0154","article-title":"A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Takahashi","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"key2026042012384700_ref154-bib154","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/JCP.0b013e318267c304","article-title":"Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology","volume":"32","author":"Wehmeier","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"key2026042012384700_ref155-bib155","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1185\/03007990903316152","article-title":"Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-na\u00efve children and adolescents with attention deficit\/hyperactivity disorder","volume":"25","author":"Montoya","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"key2026042012384700_ref156-bib156","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1087054712448252","article-title":"The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial","volume":"18","author":"Childress","year":"2014","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref157-bib157","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","article-title":"Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder","volume":"50","author":"Findling","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref158-bib158","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.euroneuro.2012.11.012","article-title":"European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"23","author":"Coghill","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"key2026042012384700_ref159-bib159","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1017\/S1092852900016898","article-title":"Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder","volume":"13","author":"Findling","year":"2008","journal-title":"CNS Spectr"},{"key":"key2026042012384700_ref160-bib160","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1542\/peds.108.4.883","article-title":"Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit\/hyperactivity disorder","volume":"108","author":"Wolraich","year":"2001","journal-title":"Pediatrics"},{"key":"key2026042012384700_ref161-bib161","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/chi.0b013e31815d9af7","article-title":"Clonidine for attention-deficit\/hyperactivity disorder: I. Efficacy and tolerability outcomes","volume":"47","author":"Palumbo","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref162-bib162","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/00048670601057767","article-title":"Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial","volume":"41","author":"Wang","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"key":"key2026042012384700_ref163-bib163","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1753-2000-5-35","article-title":"Efficacy of lisdexamfetamine dimesylate in children with attention-deficit\/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis","volume":"5","author":"Jain","year":"2011","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"key2026042012384700_ref164-bib164","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10567-023-00462-3","article-title":"Predictors of health-related quality of life in neurodivergent children: a systematic review","volume":"27","author":"Mahjoob","year":"2024","journal-title":"Clin Child Fam Psychol Rev"},{"key":"key2026042012384700_ref165-bib165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00787-009-0046-3","article-title":"The quality of life of children with attention deficit\/hyperactivity disorder: a systematic review","volume":"19","author":"Danckaerts","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref166-bib166","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/10870547231155438","article-title":"The impact of childhood attention-deficit\/hyperactivity disorder (ADHD) on children\u2019s health-related quality of life: a systematic review and meta-analysis","volume":"27","author":"Wanni Arachchige Dona","year":"2023","journal-title":"J Atten Disord"},{"key":"key2026042012384700_ref167-bib167","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00787-017-0986-y","article-title":"Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit\/hyperactivity disorder","volume":"26","author":"Coghill","year":"2017","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref168-bib168","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12402-016-0210-9","article-title":"Is there a difference between child self-ratings and parent proxy-ratings of the quality of life of children with a diagnosis of attention-deficit hyperactivity disorder (ADHD)? A systematic review of the literature","volume":"9","author":"Galloway","year":"2017","journal-title":"Atten Defic Hyperact Disord"},{"key":"key2026042012384700_ref169-bib169","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1017\/S2045796018000409","article-title":"Quality of life of parents of mentally-ill children: a systematic review and meta-analysis","volume":"28","author":"Dey","year":"2019","journal-title":"Epidemiol Psychiatr Sci"},{"key":"key2026042012384700_ref170-bib170","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"J Am Med Assoc"},{"key":"key2026042012384700_ref171-bib171","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.7326\/M21-2234","article-title":"QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies","volume":"174","author":"Yang","year":"2021","journal-title":"Ann Intern Med"},{"key":"key2026042012384700_ref172-bib172","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaac.2018.11.014","article-title":"Attention-deficit\/hyperactivity disorder, school performance, and effect of medication","volume":"58","author":"Jangmo","year":"2019","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key2026042012384700_ref173-bib173","volume-title":"Effects of Expectations, Medication and Placebo during the Quantified Behavior Test in Patients with Untreated ADHD and Substance Use Disorder","author":"2014-001488-11","year":"2014"},{"key":"key2026042012384700_ref174-bib174","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1027\/1016-9040.14.2.142","article-title":"Ambulatory activity monitoring: progress in measurement of activity, posture, and specific motion patterns in daily life","volume":"14","author":"Bussmann","year":"2009","journal-title":"Eur Psychol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/DRDR7171\/DRDR7171.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:25:17Z","timestamp":1776669917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/DRDR7171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":170,"alternative-id":["10.3310\/DRDR7171"],"URL":"https:\/\/doi.org\/10.3310\/drdr7171","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"10-2023","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"05-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"02-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}